Peptide Schedule
Bronchogen4 residuesAEDLEach bubble = one amino acid. Size = residue mass. Color = chemical class.Bronchogen
Benefits
About Bronchogen
Bronchogen is a synthetic tetrapeptide bioregulator consisting of Ala-Glu-Asp-Leu (AEDL), developed through Professor Vladimir Khavinson's bioregulation research program at the Institute of Bioregulation and Gerontology in St. Petersburg. It belongs to the "cytogen" class of synthesized short peptides designed to interact with DNA in a tissue-specific manner, targeting bronchial epithelium and pulmonary tissue. In bronchial tissue specifically, Bronchogen has been shown to regulate genes governing epithelial differentiation (NKX2-1, FOXA1, FOXA2), mucin production (MUC4, MUC5AC), and surfactant protein expression (SFTPA1). It also modulates levels of key proteins including Ki67, p53, Mcl-1, and NOS-3, with particularly pronounced effects observed in aged cell cultures. Animal studies using rat models of chronic obstructive pulmonary disease have produced encouraging results. One-month courses of Bronchogen reversed bronchial epithelial remodeling, restored ciliated cell populations, normalized inflammatory cytokine profiles, and increased secretory IgA and surfactant protein B levels. In vitro work has demonstrated the peptide's ability to stabilize DNA structure, increasing DNA melting temperature by approximately 3.1 degrees C through binding in the major groove at N7 guanine positions. Current evidence comes exclusively from preclinical research — animal models, cell cultures, and molecular studies. No controlled human clinical trials have been conducted, and the peptide isn't approved for medical use in any Western jurisdiction.
Who Should Consider Bronchogen
- Researchers studying bronchial epithelial gene regulation
- Preclinical investigators exploring COPD peptide interventions
- Individuals interested in Khavinson bioregulator protocols
- Those researching age-related respiratory tissue changes
How Bronchogen Works
Bronchogen operates through Khavinson's proposed bioregulation pathway, where short peptides interact directly with DNA to modulate tissue-specific gene expression. The tetrapeptide AEDL penetrates cell nuclei and binds preferentially to deoxyribooligonucleotides containing CNG sequences, with the ability to distinguish between methylated and unmethylated DNA regions. In bronchial tissue, the primary mechanism involves binding to gene promoter regions in the DNA major groove, specifically at N7 guanine positions. This interaction regulates transcription of genes encoding epithelial differentiation factors (NKX2-1, SCGB1A1, FOXA1, FOXA2), mucin glycoproteins, and surfactant proteins. The peptide also modulates expression of proliferation markers (Ki67), anti-apoptotic proteins (Mcl-1), tumor suppressors (p53), and endothelial nitric oxide synthase (NOS-3). In COPD models, these molecular actions translate to reduced neutrophilic inflammation, restored epithelial barrier integrity, and recovery of secretory immune function through IgA upregulation.
What to Expect
No noticeable effects expected. The peptide is beginning to interact with DNA in bronchial tissue and influence gene expression patterns at the molecular level.
Subtle changes in gene expression and protein synthesis may be underway. Some users anecdotally report easier breathing, though this hasn't been validated in controlled studies.
In animal models, measurable improvements in bronchial epithelium morphology and inflammatory markers are typically observed by the end of a 30-day course.
Bioregulator effects are theorized to persist beyond the active dosing period due to sustained changes in gene expression patterns.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Note: Bronchogen (AEDL) is a synthetic tetrapeptide bioregulator developed through Khavinson's peptide bioregulation program, targeting bronchial and pulmonary tissue. It's typically available as oral capsules (20 mg) or lyophilized powder for research. Standard protocols call for 1-2 capsules daily over 20-30 day courses, repeated every 4-6 months. As a short-chain peptide, it demonstrates oral bioavailability when formulated in enteric-coated capsules.
How to Inject Bronchogen
For oral capsule use: take 1-2 capsules (typically 10-20 mg each) once daily on an empty stomach, 15-20 minutes before a meal. Swallow whole with water — don't crush or open the enteric-coated capsules. Standard course duration is 20-30 days. Morning administration is generally preferred.
Cycling Protocol
Standard bioregulator protocol: 20-30 day oral course (1-2 capsules daily), repeated every 4-6 months. Some protocols suggest two consecutive courses with a 1-week break for initial loading.
Pharmacokinetics
Source: Estimated from tetrapeptide class kinetics; no direct PK studies on Bronchogen published. Short-chain peptides of similar MW (~446 Da) typically have half-lives under 2 hours.
Loading the interactive decay curve.
Side Effects
No adverse effects have been reported in the published preclinical literature for Bronchogen. Animal studies using the tetrapeptide over month-long courses did not document systemic toxicity or organ damage. However, human safety data doesn't exist from controlled trials. Anecdotal user reports suggest the peptide is well tolerated orally, with occasional mild gastrointestinal discomfort being the most commonly mentioned complaint. Because Bronchogen is a fully synthetic tetrapeptide rather than an animal-derived extract, prion-related concerns don't apply.
Contraindications
- Pregnancy and breastfeeding (no safety data available)
- Known hypersensitivity to any component of the peptide formulation
- Children under 18 (no pediatric safety or dosing data)
- Active acute respiratory infections (insufficient data on use during acute illness)
Drug Interactions
- No formal drug interaction studies have been conducted
- Theoretical caution with immunosuppressive medications due to IgA-modulating effects
- May interact with other Khavinson bioregulator peptides — effects of combining multiple bioregulators are unstudied
- No known interactions with standard bronchodilators or inhaled corticosteroids
Storage & Stability
Molecular Profile
Related Peptides
References
- Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostabilityPubMed 21240358
- Modulating effect of peptide therapy on bronchial epithelium in rats with obstructive lung pathologyPubMed 26468022
- Peptide regulation of gene expression and protein synthesis in bronchial epitheliumPubMed 25015171
- Penetration of short fluorescence-labeled peptides into the nucleus and specific interaction with DNAPubMed 22117547
- Antiinflammatory and regenerative effect of peptide therapy in obstructive lung pathologyPubMed 30199201